PMID- 37745614 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240402 DP - 2023 Oct 24 TI - Gene regulatory network inference from CRISPR perturbations in primary CD4+ T cells elucidates the genomic basis of immune disease. LID - 2023.09.17.557749 [pii] LID - 10.1101/2023.09.17.557749 [doi] AB - The effects of genetic variation on complex traits act mainly through changes in gene regulation. Although many genetic variants have been linked to target genes in cis, the trans-regulatory cascade mediating their effects remains largely uncharacterized. Mapping trans-regulators based on natural genetic variation, including eQTL mapping, has been challenging due to small effects. Experimental perturbation approaches offer a complementary and powerful approach to mapping trans-regulators. We used CRISPR knockouts of 84 genes in primary CD4+ T cells to perturb an immune cell gene network, targeting both inborn error of immunity (IEI) disease transcription factors (TFs) and background TFs matched in constraint and expression level, but without a known immune disease association. We developed a novel Bayesian structure learning method called Linear Latent Causal Bayes (LLCB) to estimate the gene regulatory network from perturbation data and observed 211 directed edges among the genes which could not be detected in existing CD4+ trans-eQTL data. We used LLCB to characterize the differences between the IEI and background TFs, finding that the gene groups were highly interconnected, but that IEI TFs were much more likely to regulate immune cell specific pathways and immune GWAS genes. We further characterized nine coherent gene programs based on downstream effects of the TFs and linked these modules to regulation of GWAS genes, finding that canonical JAK-STAT family members are regulated by KMT2A, a global epigenetic regulator. These analyses reveal the trans-regulatory cascade from upstream epigenetic regulator to intermediate TFs to downstream effector cytokines and elucidate the logic linking immune GWAS genes to key signaling pathways. FAU - Weinstock, Joshua S AU - Weinstock JS AD - Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD. AD - Department of Genetics, Stanford University, Stanford, CA. FAU - Arce, Maya M AU - Arce MM AD - Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA. AD - Department of Medicine, University of California, San Francisco, San Francisco, CA. FAU - Freimer, Jacob W AU - Freimer JW AD - Department of Genetics, Stanford University, Stanford, CA. AD - Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA. FAU - Ota, Mineto AU - Ota M AD - Department of Genetics, Stanford University, Stanford, CA. AD - Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA. FAU - Marson, Alexander AU - Marson A AD - Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA. AD - Department of Medicine, University of California, San Francisco, San Francisco, CA. AD - Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, 94720. AD - Institute for Human Genetics (IHG), University of California, San Francisco, San Francisco, CA, 94143. AD - Diabetes Center, University of California, San Francisco, San Francisco, CA, 94143. AD - Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA, 94129. AD - Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, 94143. AD - UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, 94158. FAU - Battle, Alexis AU - Battle A AD - Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD. AD - Malone Center for Engineering in Healthcare, Johns Hopkins University, Baltimore, MD. AD - Department of Computer Science, Johns Hopkins University, Baltimore, MD. AD - Department of Genetic Medicine, Johns Hopkins University, Baltimore, MD. FAU - Pritchard, Jonathan K AU - Pritchard JK AD - Department of Genetics, Stanford University, Stanford, CA. AD - Department of Biology, Stanford University, Stanford, CA. LA - eng GR - P30 AG073104/AG/NIA NIH HHS/United States GR - R01 HG008140/HG/NHGRI NIH HHS/United States GR - R35 GM139580/GM/NIGMS NIH HHS/United States PT - Preprint DEP - 20231024 PL - United States TA - bioRxiv JT - bioRxiv : the preprint server for biology JID - 101680187 PMC - PMC10516010 COIS- Competing Interest Declaration A.M. is a co-founder of Arsenal Biosciences, Spotlight Therapeutics, and Survey Genomics, serves on the boards of directors at Spotlight Therapeutics and Survey Genomics, is a board observer (and former member of the board of directors) at Arsenal Biosciences, is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, Amgen, Tenaya, and Lightcast, owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, Tenaya, and Lightcast and has received fees from Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Tenaya, Lightcast, GLG, Gilead, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. Patent applications have been filed based on the findings described here. J.W.F. was a consultant for NewLimit, is an employee of Genentech, and has equity in Roche. A.B. is a stockholder in Alphabet, Inc. and a consultant for Third Rock Ventures. J.S.W was a consultant to Spiral Genetics. EDAT- 2023/09/25 06:42 MHDA- 2023/09/25 06:43 PMCR- 2023/10/26 CRDT- 2023/09/25 05:03 PHST- 2023/09/25 06:42 [pubmed] PHST- 2023/09/25 06:43 [medline] PHST- 2023/09/25 05:03 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - 2023.09.17.557749 [pii] AID - 10.1101/2023.09.17.557749 [doi] PST - epublish SO - bioRxiv [Preprint]. 2023 Oct 24:2023.09.17.557749. doi: 10.1101/2023.09.17.557749.